Evaluation of Amphotericin B and Micafungin Combination Against Clinical Isolates of Aspergillus Species

REFERENCES

• Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new im-munosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not Bulating factor 2. Transplantation 1989; 47 (2): 356-359.
   Google Scholar
• Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC et al. Addition of estramustine to chemotherapy and survival of patients with cas-tration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8 (11): 994–1000.
   Google Scholar
• Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Cun- HIV/AIDS Rep 2010; 8 29.
   Google Scholar
• Comillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C et al. Comparison of epidemiological, clinical, and biological features of in-vasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43 (1): 577-584.
   Google Scholar
• Rabkin JM, Oroloff SL, Corless CL, Benner KG, Flora KD, Rosen HR et al. Association of fungal infection and increased mortality in liver trans-plant recipients. Am J Surg 2000; 179 (5): 426–430.
   Google Scholar
• Chou NK, Chi NH, Wu IW, Huang SC, Chen YS, Yu HY et al. Fungal infection in heart transplant recipients with severe sepsis: single-center ex-perience. Transplant Proc 2010; 42 (3): 952–954.
   Google Scholar
• Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, eds. The sanford guide to antimicrobial therapy 2010. 40 th ed. Sperryville: Antimicrobial therapy, Inc. 2010.
   Google Scholar
• Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clinical Pharm Thera 1999; 24 (4): 249–257.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleiner-mans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46 (8): 2546–2553.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious diseases society of America. Clin Infect Dis 2008; 46: 327–360.
   PubMed Web of Science ®Google Scholar
• Denning DW, Baily GG, Hood S. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997; 16 (4): 261–280.
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Management of Candida species in-fections in critically ill patients. Lancet Infect Dis 2003; 3 (12): 772–785.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de PipaOn M, Hernández-Caballero C, Aznar-Martin C et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54 (8): 3149–3154.
   PubMed Web of Science ®Google Scholar
• Verwell PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole re-sistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9 (12): 789–795.
   PubMed Web of Science ®Google Scholar
• Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65 (10): 2116-2118.
   Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48 (3): 693–715.
   PubMed Web of Science ®Google Scholar
• Krogstad DJ, Moellering RC. Antimicrobial combinations. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins. 1986: 537-595.
   Google Scholar
• Toyakawa M, Asari S, Nishi I, Horikawa M, Tsukamato H, Sunada A et al. In vitro combined effect of cefozopran/teicoplanin and cefozopran/ vancomycin on methicillin-resistant Staphylococcus aureus. J Chemother 2003; 15 (1): 31-36.
   Google Scholar
• Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, ampho-tericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother 2008; 15 (1): 1–5.
   Web of Science ®Google Scholar
• Arikan S, Lozano CM, Paetznick V, Rex HJ. In vitro synergy of caspo-fungin and amphotericin B against Aspergillus and Fusarium spp. Antimi-crob Agents Chemother 2002; 46 (1): 245–247.
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48 (3): 970–978.
   PubMed Web of Science ®Google Scholar
• Cuenca EM, Gomez LA, Garcia EG, Alcazar FL, Mellado E, Buitrago JM et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fu-migates. Antimicrob Agents Chemother 2005; 49 (3): 1232-1235.
   Google Scholar
• Procop GW, Roberts GD. Laboratory methods in basic mycology. Di-agnostic Microbiology. 10th ed. St. Louis: Mosby. 1998: 871-961.
   Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Con-centration-dependent effects of caspofungin on the metabolic activity of As-pergillus species. Antimicrob Agents Chemother 2007; 51 (3): 881–887.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard 2nd ed. CLSI document M38-A2. Wayne, PA: CLSI 2008; 28: 1-35.
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. The Lancet 2003; 362: 1142–1151.
   PubMed Web of Science ®Google Scholar
• Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immuno Methods 1991; 142 (2): 257–265.
   PubMed Web of Science ®Google Scholar
• Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neofor-mans in vitro. Antimicrob Agents Chemother 1997; 41 (2): 331–336.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JFGM, Bouman BA, Donnelly JP, Ver-weij PE. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39 (9): 3402–3408.
   PubMed Web of Science ®Google Scholar
• Yekutiel A, Shalit I, Shadkchan Y, Osherov N. In vitro activity of caspo-fungin combined with sulfamethoxazole against clinical isolates of As-pergillus spp. Antimicrob Agents Chemother 2004; 48 (9): 3279–3283.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidula-fungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47 (10): 3323-3325.
   Google Scholar
• Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kon-toyiannis DP et al. Patterns of susceptibility of Aspergillus isolates recov-ered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 2009; 47 (10): 3271-3275.
   Google Scholar
• Barwicz J. Tancrede P. The effect of aggregation state on ampho-tericin-B on its interactions with cholesterol- or ergosterol-containing phos-phatidylcholine monolayers. Chem Phys Lipids 1997; 85 (2): 145–155.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of As-pergillus terreus at a university hospital. J Clin Microbiol 2003; 41 (12): 5525–5529.
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the Euro-pean committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53 (2): 794–795.
   PubMed Web of Science ®Google Scholar
• Takazono T, Izumikawa K, Mihara T, Kosai K, Saijo T, Imamura Y et al. Efficacy of combination antifungal therapy with intraperitoneally admin-istered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary Aspergillosis. Antimicrob Agents Chemother 2009; 53 (8): 3508–3510.
   Google Scholar
• Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50 (2): 422-427.
   Google Scholar
• Meletiadis J, Antachopoulos C, Stergiopoulou T, Pournaras S, Roilides E, Walsh TJ. Differential fungicidal activities of amphotericin B and voricona-zole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007; 51 (9): 3329–3337.
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Com-parative in vitro pharmacodynamics of caspofungin, micafungin, and anidu-lafungin against germinated and nongerminated Aspergillus con idia. Antimicrob Agents Chemother 2008; 52 (1): 321–328.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47 (Suppl 1): S369–375.
   PubMed Web of Science ®Google Scholar